Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Followed by Surgery for Resectable Pancreatic Neuroendocrine Tumors

Next Previous
Search
Trial Profile

A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Followed by Surgery for Resectable Pancreatic Neuroendocrine Tumors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms NeoLuPaNET

    • Most Recent Events

    • 30 Aug 2024 Results ( From March 2020 to February 2023, n=31 patients) evaluating the safety of neoadjuvant 177Lu-labelled DOTA0-octreotate (177Lu-DOTATATE) followed by surgery in patients with NF-PanNETs , published in the British Journal of Surgery
    • 24 Oct 2023 Results assessing the safety and efficacy of neoadjuvant PRRT with 177Lu-DOTATATE followed by surgery in patients with resectable high-risk NF-PanNET presented at the 48th European Society for Medical Oncology Congress
    • 25 Jun 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top